AstraZeneca plans to build a cell therapy manufacturing and supply base, as well as an innovation centre, in Shanghai, according to Reuters.
The facility will produce CAR-T cell therapies, a type of cancer treatment that modifies a patient’s immune cells to target and destroy cancer.
It supports AstraZeneca’s ambition to become the first global drugmaker with full end-to-end cell therapy capabilities in the country.
Expansion in China and Asia
AstraZeneca said the new site will support the production and supply of treatments for China and other markets in Asia.
The company also plans to establish a production base for radioconjugate drugs in Guangzhou, aimed at providing cancer therapies across the Asia-Pacific region.
The expansion forms part of a wider investment plan in China running through 2030.
Related posts:
Taiwan could face delivery delay on Covid-19 Vaccine after the EU tightened vaccine export rules
Join SwedCham for a chat with Executive Vice President International and CEO China of AstraZeneca
AstraZeneca signs agreement with Chinese firm for oral obesity drug
Indonesia and Sweden launch Healthcare platform
